Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used drugs but their use is hampered by gastrointestinal side effects. Cyclo-oxygenase Inhibitor Nitric Oxide Donors (CINODs) are a new class of antiinflammatory and analgesic drugs generated by adding a nitric oxide generating moiety to the parent NSAID via an ester linkage. The combination of balanced inhibition of the two main COX isoforms with release of NO confers to CINODs a reduced gastrointestinal toxicity and a potent anti-inflammatory activity. It is suggested that the NO, which is released by the metabolism of nitrate as the compounds are broken down, may counteract the consequences of the NSAID-induced decrease in gastric mucosal prostaglandins. Recent clinical trials with CINODs (previously termed NO-NSAIDs) have provided data consistent with pre-clinical observations
Keywords: NSAID, cyclooxygenase 2, Nitric oxide, NCX-4016, gastrointestinal injury, immunomodulatory
Current Topics in Medicinal Chemistry
Title: Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status
Volume: 7 Issue: 3
Author(s): Fiorucci Stefano and Eleonora Distrutti
Affiliation:
Keywords: NSAID, cyclooxygenase 2, Nitric oxide, NCX-4016, gastrointestinal injury, immunomodulatory
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used drugs but their use is hampered by gastrointestinal side effects. Cyclo-oxygenase Inhibitor Nitric Oxide Donors (CINODs) are a new class of antiinflammatory and analgesic drugs generated by adding a nitric oxide generating moiety to the parent NSAID via an ester linkage. The combination of balanced inhibition of the two main COX isoforms with release of NO confers to CINODs a reduced gastrointestinal toxicity and a potent anti-inflammatory activity. It is suggested that the NO, which is released by the metabolism of nitrate as the compounds are broken down, may counteract the consequences of the NSAID-induced decrease in gastric mucosal prostaglandins. Recent clinical trials with CINODs (previously termed NO-NSAIDs) have provided data consistent with pre-clinical observations
Export Options
About this article
Cite this article as:
Stefano Fiorucci and Distrutti Eleonora, Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status, Current Topics in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/156802607779941350
DOI https://dx.doi.org/10.2174/156802607779941350 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Cycloaddition Methodology: A Useful Entry Towards Biologically Active Heterocycles
Current Organic Chemistry Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews New Strategies for Necrotizing Enterocolitis Diagnosis and Prevention in Newborns
Current Pediatric Reviews Plasma Substitutes Therapy in Pediatrics
Current Drug Targets An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Vascular Dementia: Atherosclerosis, Cognition and Alzheimers Disease
Current Alzheimer Research Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets New Approaches to Endothelin Receptor Antagonist-Bosentan
Letters in Organic Chemistry Novel Etomidate Derivatives
Current Pharmaceutical Design Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets